Optimization of Radium-223 Treatment of Castration-resistant Prostate Cancer Based on the Burden of Skeletal Metastasis and Clinical Parameters.

Abstract

BACKGROUND:

Radium-223 dichloride (Ra-223) is now frequently used to treat prostate cancer that has metastasized to bone, although patient selection continues to be suboptimal for determining who will benefit most from this novel treatment modality.

MATERIALS AND METHODS:

Seventy-nine patients with metastatic castration-resistant prostate cancer (mCRPC) were treated with Ra-223 from 2012 to 2016. The burden of skeletal metastasis was determined for each using the Bone Scan Index (BSI) as a ratio of diseased to normal bone. Clinical, laboratory, and survival data were collected and examined for associations with BSI, and treatment tolerability was assessed.

RESULTS:

Chemotherapy-naïve patients were significantly more likely to complete the full course of treatment. Median follow-up was 31 months (range 0.7-38.8 months) and median overall survival was 15.4 months (range 9.5-20.6 months). Overall survival was significantly associated with findings on bone scans (P < .05). Patients with higher BSI tended toward poorer outcomes. Nearly half the patients with low baseline BSI survived 3 years or more following Ra-223 treatment. By contrast, only 20% of the patients with high baseline BSI lived for 1 year, and none lived for an additional 3. Baseline BSI was significantly associated with decreased hemoglobin, higher serum PSA and alkaline phosphatase levels, and treatment-associated reductions in platelet and absolute neutrophil counts.

CONCLUSION:

Our results suggest better outcomes to Ra-223 therapy for patients who are chemotherapy-naïve and who undergo treatment earlier in the course of their disease as reflected by low BSI and concordant laboratory parameters.

• Authors: Ahmad Shariftabrizi, Shalin Kothari, Saby George, Kristopher Attwood, Ellis Levine, Dominick Lamonica
• Journal: The oncologist (Oncologist) Vol. 28 Issue 3 Pg. 246-251 (03 17 2023) ISSN: 1549-490X [Electronic] England
• PMID: 36651837 (Publication Type: Journal Article, Research Support, N.I.H., Extramural)
• Copyright: © The Author(s) 2023. Published by Oxford University Press.

Chemical References

• Radium-223
• Radium

Topics

• Male
• Humans
• Radium (therapeutic use)
• Prostatic Neoplasms, Castration-Resistant (drug therapy, radiotherapy)
• Bone Neoplasms (drug therapy)
• Bone and Bones
• Retrospective Studies